You are here

  • Home
  • Archive
  • Volume 70, Issue 12
  • Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Authors

  1. Correspondence to Jasmin B Kuemmerle-Deschner, Division of Pediatric Rheumatology, Department of Pediatrics, University Children's Hospital Tuebingen, Hoppe‑Seyler-Strasse 1, 72076 Tübingen, Germany; kuemmerle.deschner{at}uni-tuebingen.de
View Full Text

Citation

Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
Annals of the Rheumatic Diseases 2011;70:2095-2102.

Publication history

  • Accepted July 5, 2011
  • First published August 21, 2011.
Online issue publication 
October 25, 2017

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions